样式: 排序: IF: - GO 导出 标记为已读
-
Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-03-19 Kosei Sakai, Daiki Kato, Junka Yoshinaka, Yosuke Takahashi, Namiko Ikeda, Susumu Aoki, Takaaki Iguchi, Shingo Ishikawa, Norio Yamagishi, Shunsuke Shimamura, Takayuki Nakagawa
Urothelial carcinoma (UC) is the most common malignancy of the urinary tract in dogs and has aggressive behaviour. Although human epidermal growth factor receptor 2 (HER2) is a known therapeutic target with evidence in canine UC, the efficacy of anti‐HER2 antibody drugs remains unknown. This study aimed to investigate the effects of anti‐HER2 antibody drugs including trastuzumab and trastuzumab emtansine
-
Sodium iodide symporter immunolabelling as a predictor of clinical iodide uptake in canine thyroid carcinoma: A preliminary study Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-03-16 Katelin V. Dark, Owen T. Skinner, Dae Young Kim, James J. Karnia, Megan A. Mickelson, Charles A. Maitz
Thyroid follicular tumours may take up iodide via the sodium‐iodide symporter. Knowledge of iodide uptake could then allow treatment with I‐131 in dogs with high‐risk tumours. The objective of this study was to determine the relationship between clinically detectable iodide uptake (as determined by scintigraphy and/or thyroxine concentrations) and sodium iodide symporter immunohistochemical labelling
-
The role of companion animal models in radiopharmaceutical development and translation Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-03-05 Charles A. Maitz, Jeffrey N. Bryan
Advancements in molecular imaging and drug targeting have created a renaissance in the development of radiopharmaceuticals for therapy and theranostics. While some radiopharmaceuticals, such as Na[131I]I, have been used clinically for decades, new agents are being approved using small‐molecules, peptides, and antibodies for targeting. As these agents are being developed, the need to understand dosimetry
-
Urinary and household chemical exposures in pet dogs with urothelial cell carcinoma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-02-22 Samantha L. Braman, Hannah Peterson, Amy Elbe, Erin Mani, Camille Danielson, Christa Dahman, Julia D. Labadie, Lauren A. Trepanier
Urothelial cell carcinoma (UCC) has been linked to environmental chemical exposures in people, but these risk factors are not well understood in dogs with UCC. We hypothesised that household chemical exposures contribute to the risk of UCC in pet dogs. This prospective cross-sectional case–control study included 37 dogs with UCC and 37 unaffected breed-, sex-, and age-matched controls. Dog owners completed
-
Expression of mPGES1 and p16 in feline and human oral squamous cell carcinoma: A comparative oncology approach Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-02-20 Walaa Hamed Shaker Nasry, Kathleen Jones, Juan Carlos Rodriguez-Lecompte, Marvin Tesch, Chelsea K. Martin
Comparative cancer studies help us determine if discoveries in one species apply to another. Feline and human oral squamous cell carcinoma (FOSCC and HOSCC) are invasive tumours in which inflammation and abnormal p16 expression are reported. Immunohistochemistry was used to determine the expression of p16 and microsomal prostaglandin E2 synthase 1 (mPGES1) in 42 HOSCC and 45 FOSCC samples with known
-
Magnetic resonance and computed tomographic imaging characteristics and potential molecular mechanisms of feline meningioma associated calvarial hyperostosis Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-02-08 Michael R. Edwards, Josefa K. Garcia Mora, Kayla M. Fowler, Christina Vezza, John L. Robertson, Gregory B. Daniel, Richard L. Shinn, Rell L. Parker, Stephen R. Werre, John H. Rossmeisl
Meningiomas are the most common feline primary brain tumours, and calvarial hyperostosis (CH) is frequently documented in association with this neoplastic entity. The clinical significance of and mechanisms driving the formation of CH in cats with meningiomas are poorly understood, although tumour invasion into the skull and tumour production of cytokines and enzymes have been implicated as causes
-
A retrospective Italian Society of Veterinary Oncology (SIONCOV) study of 56 cats with appendicular osteosarcoma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-02-07 Laura Marconato, Maurizio Annoni, Federico Massari, Stefano Zanardi, Damiano Stefanello, Roberta Ferrari, Federica Rossi, Vincenzo Montinaro, Emanuela Morello, Carmit Chalfon, Marco De Lorenzi, Daniela Murgia, Dario Drudi, Gabriele Truncellito, Emanuele Cabibbo, Silvia Sabattini
Osteosarcoma is the most common malignant primary bone cancer, but it is infrequently reported in cats. Feline appendicular osteosarcoma typically exhibits good prognosis when treated with surgery alone. A retrospective multi-institutional study was conducted to identify possible prognostic factors. Cats diagnosed with appendicular osteosarcoma were included if initial staging and follow-up information
-
Plasma cell-free DNA in canine lymphoma patients as a novel material for genotyping Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-01-29 Satoshi Kambayashi, Nanae Ono, Tomofumi Tone, Kenji Baba, Masaru Okuda
Canine lymphoma is a disease with high morbidity and poor long-term prognosis, despite a high response rate to chemotherapy. In this study, we focused on liquid biopsy, in which small amounts of substances from body fluids were analysed, to determine whether cell-free DNA (cfDNA) in the plasma can be used as a biomarker for lymphoma in dogs. We found that 23 patients with lymphoma had significantly
-
-
Author Index Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-02-01
A Abadie, J. 4 Aceña, C. 17 Ahrens, C. 7 Aluai-Cunha, C. 10 Amador, S. T. 12 Andersson, G. 8 Aravena, G. 17 Aresu, L. 16 Armando, F. 15 Arteaga, T. 5 Asano, K. 12, 16 Auletta, L. 6 B Bailén Goméz, M. 18 Barett, L. 3, 4 Baumgärtner, W. 15 Beatrice, L. 7 Beaudu-Lange, C. 3, 4 Becavin, S. 4 Beebe, E. 9 Beer, P. 10 Benoit, J. 3, 4 Béguin, J. 3, 4 Bismuth, C. 16 Bley, C. R. 7 Bodet-Milin, C. 4 Boissy, L
-
Outcomes of 35 dogs with craniomaxillofacial osteosarcoma treated with stereotactic body radiation therapy Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-01-21 Johnny Altwal, Ber-In Lee, Mary-Keara Boss, Susan M. LaRue, Tiffany Wormhoudt Martin
Canine craniomaxillofacial osteosarcoma (OSA) is most commonly treated surgically; however, in cases where surgery is not feasible or non-invasive treatment is desired, stereotactic body radiation therapy (SBRT) may be elected for local tumour control. In this study, we evaluated 35 dogs treated with SBRT. Nine dogs (26%) had calvarial, seven (20%) had mandibular and 19 (54%) had maxillary OSA. Median
-
Mastocytosis in the skin in dogs: A multicentric case series Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-01-20 Eleanor K. Wyatt, Verena Affolter, Stefano Borio, Alexandra Guillen, Sara Verganti, Sue Murphy, Damiano Ballarini, Frane Banovic, Vanessa Schmidt, Jean-Benoit Tanis
Canine cutaneous mastocytosis (CM) is rare in contrast to canine mast cell tumours. In humans, CM commonly affects children and is usually indolent with possible spontaneous resolution. Systemic mastocytosis (SM) with bone marrow involvement typically affects adults, can have a poor outcome, and often includes skin lesions. ‘Mastocytosis in the skin’ (MIS) is the preferred term of skin lesions, if
-
Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-01-18 Nicholas E. Prevedel, Miles W. Mee, Geoffrey A. Wood, Brenda L. Coomber
The standard treatment for canine lymphoma is the CHOP chemotherapy regimen. Proteasome inhibitors have been employed with CHOP for the treatment of human haematological malignancies but remain to be fully explored in canine lymphoma. We identified an association between poor response to CHOP chemotherapy and high mRNA expression levels of proteasomal subunits in a cohort of 15 canine lymphoma patients
-
Correction to: Standardization of canine meningioma grading: Validation of new guidelines for reproducible histopathologic criteria Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-01-11
Belluco, S, Marano, G, Lurier, T, et al. Standardization of canine meningioma grading: validation of new guidelines for reproducible histopathologic criteria. Vet Comp Oncol 2023. 10.1111/vco.12932 The cut-off values reported in the present article were derived from the study titled “Belluco S, Marano G, Baiker K, et al. Standardization of canine meningioma grading: Inter-observer agreement and recommendations
-
Correction to: Standardization of canine meningioma grading: Inter-observer agreement and recommendations for reproducible histopathologic criteria Vet. Comp. Oncol. (IF 2.1) Pub Date : 2024-01-11
Belluco S, Marano G, Baiker K, et al. Standardization of canine meningioma grading: inter-observer agreement and recommendations for reproducible histopathologic criteria. Vet Comp Oncol. 2022;20:509–520. In the discussion section of the article, we incorrectly stated, “The WHO human meningioma classification cut-off of 4 and 20 mitoses is assessed in 1.60 mm2, consisting of the area obtained by counting
-
Large granular lymphocyte lymphoma in 65 dogs (2005–2023) Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-12-29 Andrew D. Yale, Asia L. Crawford, Irina Gramer, Alexandra Guillén, Isabelle Desmas, Emma J. Holmes
Large granular lymphocyte lymphoma (LGLL) is a rare form of lymphoma in dogs. Limited information exists regarding presentation, treatment response, and outcome. The aim of this single-institute, retrospective study was to characterise clinical presentation, biologic behaviour, outcomes, and prognostic factors for dogs with LGLL. Cytologic review was also performed. Sixty-five dogs were included. The
-
Treatment of feline intermediate to high-grade alimentary lymphoma: A retrospective evaluation of 55 cats treated with the VAPC combination chemotherapy protocol (2017–2021) Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-12-28 Antony Stewart Moore, Angela Erica Frimberger
The most commonly utilized protocols to treat lymphoma in cats employ vincristine, cyclophosphamide and prednisone; with additional drugs sometimes used including L-asparaginase and doxorubicin. Medical records were reviewed for 55 cats with alimentary lymphoma treated with a novel multiagent protocol using prednisolone, L-asparaginase, doxorubicin, vinblastine instead of vincristine, a higher dosage
-
Evaluation of the health-related quality of life in dogs following intracranial meningioma resection using a specifically developed questionnaire Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-12-27 Chiara Köcher, Alexander Tichy, Gabriele Gradner
As advanced treatments are becoming increasingly feasible in veterinary medicine, the evaluation of the health-related quality of life (HRQOL) of treated animals is becoming more relevant. We evaluated owner-perceived HRQOL of 10 dogs that underwent craniotomy for meningioma resection between 2002 and 2022 at our institution through telephone interview. For this purpose, we developed a disease-specific
-
Elevated expression of miR-301a and its functional roles in canine oral melanoma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-12-26 MD Nazmul Hasan, Md. Mahfuzur Rahman, Al Asmaul Husna, Mohammad Arif, Tomoko Iwanaga, Kyoko Tsukiyama-Kohara, Indre Jasineviciute, Daiki Kato, Takayuki Nakagawa, Naoki Miura
miR-301a is one of numerous dysregulated microRNAs (miRNAs) in canine oral melanoma (COM), one of which is miR-301a (upregulated). Its biological role has been described in various human cancer types, including malignant melanoma, but not in COM. Accordingly, in this study, we investigated miR-301a expression in COM in greater detail to ascertain whether it could serve as a diagnostic biomarker, elucidate
-
Dysregulated miRNAs in a canine model of haemangiosarcoma metastatic to the brain Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-12-19 Silvia Sabattini, Vito Antonio Baldassarro, Riccardo Zaccone, Laura Calzà, Luciana Giardino, Marta Vascellari, Luca Lorenzini, Marzia Moretti, Laura Marconato
Haemangiosarcoma is a highly metastatic and lethal cancer of blood vessel-forming cells that commonly spreads to the brain in both humans and dogs. Dysregulations in phosphatase and tensin (PTEN) homologue have been identified in various types of cancers, including haemangiosarcoma. MicroRNAs (miRNAs) are short noncoding single-stranded RNA molecules that play a crucial role in regulating the gene
-
Homoharringtonine induces apoptosis of mammary carcinoma cells by inhibiting the AKT/mTOR signaling pathway Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-12-11 Xue Zhang, Chen Mei, Zhixuan Liang, Yan Zhi, Haojun Xu, Hongjun Wang, Hong Dong
Mammary tumour is the most common type of tumour in dogs, especially in unneutered female dogs. Homoharringtonine (HHT) is a natural alkaloid that can be used to treat various types of human tumour. However, the inhibitory effect and mechanism of HHT on canine mammary carcinomas (CMC) remain unclear. This study aimed to evaluate the inhibitory effect of HHT on CMC in vitro and determine its underlying
-
Genomic analysis across 53 canine cancer types reveals novel mutations and high clinical actionability potential Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-12-05 Sharadha Sakthikumar, Manisha Warrier, Derick Whitley, Salvatore Facista, Jonathan Adkins, Sara Aman, Darwin Tsinajinnie, Natalie Duran, Giulia Siravegna, Zeeshan Ahmed, Kenneth Day, Brooklyn Jenkins, Nidhi Patel, Kirk Ryden, Joe Nadai, Kathryn Banovich, Barbara Powers, Jeffrey Edwards, Jennifer Steinberg, Susan Fielder, Shukmei Wong, Sara A. Byron, Tyler Izatt, Victoria Zismann, Martin Boateng, Zhanyang
A genomic understanding of the oncogenic processes and individual variability of human cancer has steadily fueled improvement in patient outcomes over the past 20 years. Mutations within tumour tissues are routinely assessed through clinical genomic diagnostic assays by academic and commercial laboratories to facilitate diagnosis, prognosis and effective treatment stratification. The application of
-
Correlation between computed tomography and histological evaluation of nodal metastasis in dogs with mast cell tumours Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-12-03 Hiroshi Miyagi, Katy L. Townsend, Alyssa Michael Ettinger, Duncan S. Russell, James C. Colee, Lauren Elizabeth Newsom
Early diagnosis of nodal metastasis has been shown to impact prognosis for dogs with mast cell tumours (MCT). The objective of this retrospective study was to determine the correlation between computed tomographic characteristics of lymph nodes and histologic nodal metastasis using the HN classification system, in dogs with cutaneous or subcutaneous MCT and regional lymph node(s) removal. Dogs that
-
Comparison of the anticancer effects of various statins on canine oral melanoma cells Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-12-03 Takuro Ishikawa, Nanami Irie, Jiro Tashiro, Tomohiro Osaki, Tomoko Warita, Katsuhiko Warita, Munekazu Naito
Canine oral melanoma is a highly malignant cancer with a poor prognosis. Statins, commonly used drugs for treating dyslipidemia, exhibit pleiotropic anticancer effects and marked anti-proliferative effects against melanoma cells. The anticancer effects among statins vary; in human cancers, lipophilic statins have shown stronger anticancer effects compared with hydrophilic statins. However, data on
-
Spotlight on capecitabine for the treatment of unresectable or metastatic carcinoma of various origin: A retrospective study of 25 dogs Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-12-01 Chiara Agnoli, Sofia Rimondi, Giulia Ghisoni, Dina Guerra, Michele Tumbarello, Simone Perfetti, Alessandro Tirolo, Laura Marconato
Capecitabine, the oral prodrug of 5-fluorouracil, is indicated in people to treat various malignant epithelial cancers. In dogs, capecitabine has not been extensively evaluated. The aim of this retrospective study was to investigate toxicity and preliminary efficacy of single agent capecitabine in dogs with advanced malignant epithelial cancers of any site, for which no effective therapy existed, conventional
-
Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial–mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-11-29 Gennaro Altamura, Manuela Martano, Anna Matrone, Annunziata Corteggio, Giuseppe Borzacchiello
Feline oral squamous cell carcinoma (FOSCC) is characterised by invasive and metastatic behaviour and is poorly responsive to current treatments, hence the need for new therapeutic strategies. FOSCC shares molecular targets with human head and neck squamous cell carcinoma (HNSCC), among these the epidermal growth factor receptor. Cetuximab is an anti-epidermal growth factor receptor monoclonal antibody
-
Effects of a high-protein, increased-fibre, dry diet supplemented with omega-3 fatty acids on quality of life in dogs undergoing chemotherapy Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-11-07 Cailin R. Heinze, Kristine E. Burgess, Lisa G. Barber, Kenneth M. Rassnick, Gerald S. Post, Richard Segaloff, Julie Bayle
Quality of life (QOL) in dogs with cancer is a key consideration in the assessment of cancer treatment options. Despite interest in dietary strategies to improve management of oncology patients, there have been very few clinical studies showing the impact of diet on adverse effects of chemotherapy in dogs. This study was a randomised, controlled, double-blinded, multicenter clinical trial to investigate
-
Impact of palliative-intent radiotherapy with or without chemotherapy on lameness in flat coat retrievers with localised periarticular histiocytic sarcoma – a retrospective cohort, single institution study Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-11-07 Petros Odatzoglou, Thomas Kearns, Charlie Pittaway, Jane M. Dobson
Histiocytic sarcoma (HS) is a common tumour in flat coat retrievers (FCRs) often affecting periarticular tissues and joints. Palliative-intent radiotherapy, seeks to achieve local tumour control, pain relief and improve limb function. However, the effect of palliative-intent radiotherapy on analgesic levels of dogs with localised HS has not been studied. We hypothesised that palliative-intent radiotherapy
-
Splenic stromal sarcomas in dogs: Outcome and clinicopathological prognostic factors in 32 cases Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-11-02 Roberta Ferrari, Laura Marconato, Patrizia Boracchi, Damiano Stefanello, Francesco Godizzi, Daniela Murgia, Valentina Schievenin, Maria Amati, Eugenio Faroni, Paola Roccabianca
Due to the low frequency and the changes in diagnostic techniques and terminology during the last few years, only little clinical information is available on splenic stromal sarcoma (SSS). This multi-institutional study aimed at gathering clinical cases of SSS in dogs and investigates their clinical behaviour, as well as analyse possible clinicopathological prognostic factors, including the use of
-
Correction to: Retrospective analysis of outcome and prognostic factors of subcutaneous mast cell tumours in dogs undergoing surgery with or without adjuvant treatment Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-10-17
Treggiari E, Valenti P, Porcellato I, Maresca G, Romanelli G. Retrospective analysis of outcome and prognostic factors of subcutaneous mast cell tumours in dogs undergoing surgery with or without adjuvant treatment. Vet Comp Oncol. 2023;21(3):437-446. doi:10.1111/vco.12902 In the originally published version of this article the author first names were presented as initials only. The correct full names
-
Leading the pack: Best practices in comparative canine cancer genomics to inform human oncology Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-10-01 Cheryl A. London, Heather Gardner, Shaying Zhao, Deborah W. Knapp, Sagar M. Utturkar, Dawn L. Duval, Melissa R. Chambers, Elaine Ostrander, Jeffrey M. Trent, Gina Kuffel
Pet dogs develop spontaneous cancers at a rate estimated to be five times higher than that of humans, providing a unique opportunity to study disease biology and evaluate novel therapeutic strategies in a model system that possesses an intact immune system and mirrors key aspects of human cancer biology. Despite decades of interest, effective utilization of pet dog cancers has been hindered by a limited
-
Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-09-21 Timothy Estabrooks, Anastasia Gurinovich, Jodie Pietruska, Benjamin Lewis, Garrett Harvey, Gerald Post, Lindsay Lambert, Aubrey Miller, Lucas Rodrigues, Michelle E. White, Christina Lopes, Cheryl A. London, Kate Megquier
Canine hemangiosarcoma (HSA) is an aggressive cancer of endothelial cells with short survival times. Understanding the genomic landscape of HSA may aid in developing therapeutic strategies for dogs and may also inform therapies for the rare and aggressive human cancer angiosarcoma. The objectives of this study were to build a framework for leveraging real-world genomic and clinical data that could
-
Surgical and oncologic outcomes in dogs with malignant peripheral nerve sheath tumours arising from the brachial or lumbosacral plexus Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-09-20 Rebecca Stokes, Brandan G. Wustefeld-Janssens, Whitney Hinson, Dominique J. Wiener, Danielle Hollenbeck, Judith Bertran, Megan Mickelson, Carolyn L. Chen, Laura Selmic, Ali Aly, Galina Hayes
Malignant peripheral nerve sheath tumours (MPNST) of a plexus nerve or nerve root cause significant morbidity and present a treatment challenge. The surgical approach can be complex and information is lacking on outcomes. The objective of this study was to describe surgical complication rates and oncologic outcomes for canine MPNST of the brachial or lumbosacral plexus. Dogs treated for a naïve MPNST
-
Sensitivity of osteosarcoma cell lines to autophagy inhibition as determined by pharmacologic and genetic manipulation Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-09-18 Daniel L. Gustafson, Lindsey O. Viola, Christina G. Towers, Sunetra Das, Dawn L. Duval, Kristen M. Van Eaton
Pharmacologic inhibition of autophagy can be achieved using lysosomotropic agents such as hydroxychloroquine (HCQ) that interfere with fusion of the autophagosome to the lysosome thus preventing completion of the recycling process. The goal of the present study is to determine the sensitivity of eight canine (cOSA) and four human (hOSA) osteosarcoma tumour cell lines to antiproliferative and cytotoxic
-
Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-09-14 Mohamed Issam Atmane, Anne-Laurence Vigneau, Francis Beaudry, Charlène Rico, Derek Boerboom, Marilène Paquet
The Hippo signalling pathway is involved in breast cancer and canine mammary tumour (CMT). This study sought to evaluate the efficacy of fluvastatin on the Hippo pathway and its main effectors, YAP and TAZ, in vivo in a murine CMT cell line xenograft model. On treatment day 1, mice were divided into four groups: vehicle, fluvastatin, doxorubicin or a combination therapy. Tumour volumes were monitored
-
Efficacy and toxicity of carboplatin in the treatment of macroscopic mesenchymal neoplasia in dogs Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-09-13 Céleste Pritchard, Sami Al-Nadaf, Robert B. Rebhun, Jennifer L. Willcox, Katherine A. Skorupski, Amandine Lejeune
Palliative chemotherapy options for dogs with macroscopic non-osseous mesenchymal tumours are limited. The purpose of this study was to assess the response rate of these tumours to carboplatin chemotherapy. Medical records of 28 dogs treated with carboplatin for macroscopic mesenchymal neoplasia between 1990 and 2022 were retrospectively reviewed. Sixteen dogs with soft tissue sarcoma and 12 dogs with
-
Inhibitory checkpoint molecule mRNA expression in canine soft tissue sarcoma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-09-07 Valentina Beatriz Stevenson, Erwin Kristobal Gudenschwager-Basso, Shawna Klahn, Tanya LeRoith, William R. Huckle
Canine soft tissue sarcomas (STS) are common neoplasms and considered immune deserts. Tumour infiltrating lymphocytes are sparse in STS and, when present, tend to organize around blood vessels or at the periphery of the neoplasm. This pattern is associated with an immunosuppressive tumour microenvironment linked to overexpression of molecules of the PD-axis. PD-1, PD-L1 and PD-L2 expression correlates
-
Risk factors influencing death prior to discharge in 302 dogs undergoing unilateral adrenalectomy for treatment of primary adrenal gland tumours Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-08-31 Hunter J. Piegols, Brittany E. Abrams, Janis M. Lapsley, Megan T. Cray, Josephine A. Dornbusch, Christina Murphy, Brandan G. Wustefeld-Janssens, Carlos H. Souza, Marine Traverson, Pierre Amsellem, Elroy Williams, Owen T. Skinner, Julius M. Liptak, Julie A. Stephens, Laura E. Selmic
Adrenalectomies for canine adrenal tumours are associated with peri-operative morbidity and mortality. Objectives of this study included assessing the prognostic value of tumour- or surgery-related variables in predicting peri-operative mortality and overall survival in dogs undergoing adrenalectomies for primary adrenal tumours as well as pre-treatment with phenoxybenzamine on survival to discharge
-
Extracellular heat shock protein 70 levels in tumour-bearing dogs and cats treated with radiation therapy and hyperthermia Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-08-31 K. J. Nytko, M. S. Weyland, S. Dressel-Böhm, S. Scheidegger, L. Salvermoser, C. Werner, S. Stangl, A. C. Carpinteiro, B. Alkotub, G. Multhoff, S. Bodis, C. Rohrer Bley
Hyperthermia is a form of a cancer treatment which is frequently applied in combination with radiotherapy (RT) to improve therapy responses and radiosensitivity. The mode of action of hyperthermia is multifactorial; the one hand by altering the amount of the blood circulation in the treated tissue, on the other hand by modulating molecular pathways involved in cell survival processes and immunogenic
-
Descriptive analysis of haemangiosarcoma occurrence in dogs enrolled in the Golden Retriever lifetime study Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-08-27 Alison Hillman, Brenna Swafford, Camille Delavenne, Hille Fieten, Kim Boerkamp, Kathy Tietje
Haemangiosarcoma is a relatively common malignant tumour in dogs, and one of the primary outcomes of interest for the Golden Retriever Lifetime Study. This study collects longitudinal data and samples from a cohort of golden retrievers, with the aim of identification of nutritional, genetic, environmental, lifestyle and reproductive risk factors for cancers and other important diseases in dogs. This
-
Standardization of canine meningioma grading: Validation of new guidelines for reproducible histopathologic criteria Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-08-27 Sara Belluco, Giuseppe Marano, Thibaut Lurier, Giancarlo Avallone, Chiara Brachelente, Stefano Di Palma, Roberta Rasotto, Kerstin Baiker, Andreas Beineke, Anna Oevermann, Frauke Seehusen, Fabiano José Ferreira de Sant'Ana, Patrizia Boracchi, Martí Pumarola, Maria Teresa Mandara
Canine meningiomas are currently graded using the human grading system. Recently published guidelines have adapted the human grading system for use in dogs. The goal of this study was to validate the new guidelines for canine meningiomas. To evaluate the inter-observer agreement, 5 veterinary surgical pathologists graded 158 canine meningiomas following the human grading system alone or with the new
-
Retrospective study evaluating the efficacy of stereotactic body radiation therapy for the treatment of confirmed or suspected primary pulmonary carcinomas in dogs Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-08-24 Tiffany Wormhoudt Martin, Susan M. LaRue, Lynn Griffin, Del Leary, Mary-Keara Boss
Canine primary pulmonary carcinomas (PCCs) are commonly treated with surgery with overall median survival times (MST) around a year; however, due to extent of disease, prognosis, or client preference, alternative treatments have been considered. Stereotactic body radiation therapy (SBRT) has been utilized in human cancer patients for local control of lung tumours as a surgical alternative. Twenty-one
-
Stereotactic radiotherapy outcomes for intraventricular brain tumours in 11 dogs Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-08-21 Katherine Sarah Hansen, Chai Fei Li, Alain Pierre Théon, Michael Sean Kent
Published radiotherapy data for canine intraventricular tumours are limited. In this retrospective, longitudinal study (9/2011–2018), 11 dogs with intraventricular masses were treated with stereotactic radiotherapy (SRT). Pathologic diagnosis was available from surgery or necropsy in 6/11 cases, revealing choroid plexus papilloma (3) or carcinoma (2), and ependymoma (1). The remainder were magnetic
-
Cover Image Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-08-14 Morgan S. Schrock, Abigail A. Zalenski, Miranda M. Tallman, Luke Kollin, Anna Bratasz, Griffin Weeks, Margaret A. Miller, Courtney N. Sweeney, G. Elizabeth Pluhar, Michael R. Olin, William C. Kisseberth, R. Timothy Bentley, Peter J. Dickinson, Daniel York, Amy Webb, Xu Wang, Sarah Moore, Monica Venere, Matthew K. Summers
The cover image is based on the Original Article Establishment and characterization of two novel patient-derived lines from canine high-grade glioma by Morgan S. Schrock et al., https://doi.org/10.1111/vco.12912.
-
Patterns of metastatic progression and association with clinical outcomes in canine osteosarcoma: A necropsy study of 83 dogs Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-08-17 K. I. Silver, S. Patkar, C. Mazcko, E. P. Berger, J. A. Beck, A. K. LeBlanc
Osteosarcoma is a highly metastatic primary bone tumour that occurs spontaneously in both pet dogs and humans. Patterns of metastasis to organs beyond the most common site (lung) are poorly characterised and it is unknown whether specific associations between patterns of metastatic progression and patient features exist. This retrospective study characterised the necropsy findings of 83 dogs receiving
-
Thromboelastographic results and hypercoagulability in dogs with surgically treated hepatocellular adenoma and carcinoma: A Veterinary Society of Surgical Oncology prospective study Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-07-27 Gabrielle S. Fontes, Vincent A. Wavreille, Janis M. Lapsley, Edward S. Cooper, Julien Guillaumin, Laura E. Selmic
The most common haemostatic abnormality in dogs with cancer is hypercoagulability. A transient hypercoagulability has been documented in people with hepatocellular carcinoma (HCC) that resolves within weeks following hepatic tumour resection.
-
Clinical outcomes in cats with renal carcinoma undergoing nephrectomy: A retrospective study Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-07-19 Shannon A. Kenny, Matthew R. Cook, Jennifer A. Lenz, Karl C. Maritato, Katherine A. Skorupski, Brandan G. Wustefeld-Janssens, MacKenzie A. Pellin, Catrina J. Silveira, Stan Veytsman, Laura E. Selmic, Brian D. Husbands
Renal carcinomas (RC) are uncommonly encountered in feline medicine. Limited information regarding clinical presentation and postoperative outcomes is available. The purpose of this multi-institutional, retrospective study was to describe the presenting features and clinical outcomes of cats with RC undergoing nephrectomy. Thirty-six client-owned cats were included. Medical records from participating
-
The second-generation curcumin analogue RL71 elicits G2/M cell cycle arrest and apoptosis in canine osteosarcoma cells Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-07-12 Barnaby Kelly, Douglas Thamm, Rhonda J. Rosengren
Canine osteosarcoma is an aggressive cancer, comprising 85% of canine bone neoplasms. Current treatment practices of surgery and chemotherapy increase 1-year survival by only 45%. The curcumin analogue RL71, has demonstrated potent in vitro and in vivo efficacy in several models of human breast cancer through increased apoptosis and cell cycle arrest. Thus, the present study aimed to investigate efficacy
-
Efficacy of stereotactic radiation therapy for the treatment of confirmed or presumed canine glioma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-07-09 Erin Trageser, Tiffany Martin, Braden Burdekin, Cullen Hart, Del Leary, Susan LaRue, Mary-Keara Boss
Intracranial gliomas are the second most common brain tumour in dogs. Radiation therapy provides a minimally invasive treatment option for this tumour type. Earlier publications reporting on the use of non-modulated radiation therapy suggested a poor prognosis for dogs with glioma, with median survival times ranging between 4 and 6 months; more recent literature utilizing stereotactic radiation therapy
-
A multi-centre prospective evaluation of internet research habits among owners seeing a veterinary oncologist Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-06-25 Jennifer Hauss, Mairin E. Miller, Colleen Tansey, Donald Szlosek, Lisa A. Murphy, Reid K. Nakamura
The purpose of this study is to evaluate the internet-use among pet owners seeing a veterinary oncologist. Over a two-month period, 137 questionnaires were collected at three specialty hospitals around a large urban city. Approximately 85% of respondents reported using the internet to research their pet's condition and/or treatment. A search engine was the most employed means however veterinary university
-
Quantification of circulating tumour cells over time in dogs with appendicular osteosarcoma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-06-19 Tanya F. Wright, Brigitte A. Brisson, Catherine R. Belanger, Angela Tiessen, Victoria Sabine, Karolina Skowronski, Geoffrey A. Wood, Michelle L. Oblak, Anthony J. Mutsaers, William Sears, Dorothee Bienzle
Enumeration of circulating tumour cells (CTC) has shown promise for prognostication and guidance of therapeutic decisions in human cancers. The objective of this study was to enumerate CTC over time in dogs with naturally occurring osteosarcoma (OSA), and to determine correlation with patient outcome. Twenty-six dogs with OSA and no evidence of metastatic disease at the time of amputation were enrolled
-
New molecular targets in canine hemangiosarcoma—Comparative review and future of the precision medicine Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-06-12 Karolina Małgorzata Kapturska, Aleksandra Pawlak
Human angiosarcoma and canine hemangiosarcoma reveal similarities not only in their aggressive clinical behaviour, but especially in molecular landscape and genetic alterations involved in tumorigenesis and metastasis formation. Currently, no satisfying treatment that allows for achieving long overall survival or even prolonged time to progression does not exist. Due to the progress that has been made
-
Newcastle disease virus LaSota strain induces apoptosis and activates the TNFα/NF-κB pathway in canine mammary carcinoma cells Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-06-06 Jiahui Wang, Mengqing Li, Meng Li
Spontaneous canine mammary carcinomas (CMCs) have been widely considered a good research model for human breast cancers, which brings much attention to CMCs. In recent years, the oncolytic effect of Newcastle disease virus (NDV) on cancer cells has been widely studied, but its effect on CMCs is still unclear. This study aims to investigate the oncolytic effect of NDV LaSota strain on canine mammary
-
Cyclical 10-day dosing of melphalan for canine multiple myeloma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-06-05 Lucy Teddy, Skylar R. Sylvester, Kelly S. O'Connor, Kelly R. Hume
Canine multiple myeloma (MM) is typically treated with melphalan chemotherapy. A protocol with repeated 10-day cyclical dosing of melphalan has been used at our institution but has not been described in the literature. Our objectives were to describe the outcome and adverse events of this protocol in a retrospective case series. We hypothesised the cyclical 10-day protocol would have similar outcomes
-
Establishment and characterization of two novel patient-derived lines from canine high-grade glioma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-05-30 Morgan S. Schrock, Abigail A. Zalenski, Miranda M. Tallman, Luke Kollin, Anna Bratasz, Griffin Weeks, Margaret A. Miller, Courtney N. Sweeney, G. Elizabeth Pluhar, Michael R. Olin, William C. Kisseberth, R. Timothy Bentley, Peter J. Dickinson, Daniel York, Amy Webb, Xu Wang, Sarah Moore, Monica Venere, Matthew K. Summers
High-grade glioma is an aggressive cancer that occurs naturally in pet dogs. Canine high-grade glioma (cHGG) is treated with radiation, chemotherapy or surgery, but has no curative treatment. Within the past eight years, there have been advances in our imaging and histopathology standards as well as genetic charactereization of cHGG. However, there are only three cHGG cell lines publicly available
-
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-05-29 Sharadha Sakthikumar, Salvatore Facista, Derick Whitley, Sara A. Byron, Zeeshan Ahmed, Manisha Warrier, Zhanyang Zhu, Esther Chon, Kathryn Banovich, David Haworth, William P. D. Hendricks, Guannan Wang
The accrual of cancer mutation data and related functional and clinical associations have revolutionised human oncology, enabling the advancement of precision medicine and biomarker-guided clinical management. The catalogue of cancer mutations is also growing in canine cancers. However, without direct high-powered functional data in dogs, it remains challenging to interpret and utilise them in research
-
A multi-institutional epidemiologic study evaluating environmental risk factors for feline oral squamous cell carcinoma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-05-27 Lucie Noall, Suhwon Lee, Jenna H. Burton, Taya M. Marquardt, Justin Cermak, Lori A. Thombs, Anita M. Rogic, Jeffrey N. Bryan, Shirley Chu
Feline oral squamous cell carcinoma (FOSCC) is an aggressive cancer in domestic cats that has no effective treatment option when advanced. Preventative or early diagnostic measures are thus crucial. FOSCC is also a model for human head and neck SCC (HNSCC); strong risk factors in HNSCC include exposure to alcohol, tobacco, areca nut, and high-risk human papillomavirus. Previous studies have identified
-
Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-05-24 Kelley Zimmerman, Koranda A. Walsh, Jonathan T. Ferrari, Nicholas S. Keuler, Matthew J. Atherton, Jennifer A. Lenz
Multi-agent chemotherapy successfully induces remission in most naïve, high-grade canine lymphoma patients; however, disease recurrence is common. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) is an effective rescue protocol used to re-induce remission, but is associated with gastrointestinal toxicity and can be a less desirable option for patients that previously failed vincristine-containing
-
Sentinel lymph node mapping in canine mast cell tumours using a preoperative radiographic indirect lymphography: Technique description and results in 138 cases Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-05-16 Maurizio Annoni, Simone Borgonovo, Marina Aralla
Several sentinel lymph node (SLN) mapping techniques, to detect nodal metastasis in canine tumours have been investigated in the last 10 years in veterinary oncology. The purpose of this prospective study was to describe a reliable, quick, and inexpensive technique for SLN mapping in canine patients affected by cutaneous and subcutaneous mast cell tumours (MCT). Eighty dogs were enrolled in this study
-
Conventional fractionated radiotherapy outcomes for young dogs with nephroblastoma of the spinal cord: 5 cases Vet. Comp. Oncol. (IF 2.1) Pub Date : 2023-05-15 Jaeyoung Kim, Michael Sean Kent, Alain Pierre Théon, Amandine Tamara Lejeune, Katherine Sarah Hansen
Published radiotherapy results for spinal nephroblastomas in dogs are limited. In this retrospective longitudinal study (1/2007–1/2022), five dogs with a median age of 2.8 years received post-operative 3D conformal, conventional fractionated radiotherapy (CFRT) with 2–4 fields (parallel-opposed with or without two hinge-angle fields), for an incompletely resected nephroblastoma. Clinical findings prior